Immunotherapy Charts New Course for Resectable NSCLC Treatment Immunotherapy Charts New Course for Resectable NSCLC Treatment

Three cycles of neoadjuvant nivolumab plus chemotherapy improved long-term clinical outcomes in patients with resectable stage IB-IIIA NSCLC.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news